• Type:

Quality control of IPSC-derived clinical products

Play

Shin Kawamata, MD, PhD, Director of the R&D Center for Cell Therapy at the FBRI (Kobe, Japan) stresses the importance of controlling the quality of iPSC banks at a very early stage, including CiRA cell lines, to meet safety guidelines at clinical stages.

Reviews for Quality control of IPSC-derived clinical products

There are currently no reviews for Quality control of IPSC-derived clinical products
Scroll to top